Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway Activation

Karan Patel, Joseph Edward Haigh, Samuel Rack, Hitesh Mistry, Emily Heathcote, Guy N. J. Betts, Kevin Harrington, Robert Metcalf · 2026

Read Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway Activation by Karan Patel, Joseph Edward Haigh, Samuel Rack, Hitesh Mistry, Emily Heathcote, Guy N. J. Betts, Kevin Harrington, Robert Metcalf (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13297407.txt.

Description

A count of mutations per tumor might help sort a rare gland cancer into risk groups, a 2026 study led by Karan Patel hints. The team worked with people whose adenoid cystic cancer had spread or come back and could not be cured.

In two groups of patients, they counted mutations and set the counts next to gene types and survival time. Counts were low in most tumors. Cancers with switched-on NOTCH genes tended to score higher. The team says counts like these could sharpen how doctors group patients by risk. That step could help match people to immune drugs, which tend to work best when mutation counts run high.

Catalog record

CREATORKaran Patel, Joseph Edward Haigh, Samuel Rack, Hitesh Mistry, Emily Heathcote, Guy N. J. Betts, Kevin Harrington, Robert Metcalf
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24396
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13297407

Browse the full library · About the Tower of Babel